Compare GeneDx Holdings Corp (WGS) vs Block Inc (XYZ) Price & Performance

WGS trades at $85.87, down 0.14% today, with a bullish technical signal from moving averages and support at $84. The company reported Q2 2026 revenue of $114.4M, beating estimates, and returned to adjusted profitability early. However, net income remains negative at -$106M for 2026, with high valuation multiples like EV/EBITDA of 161.17. Recent news highlights partnerships and product launches, such as the NPC GenomeComplete initiative with Beren Therapeutics.

Outlook is mixed: strong analyst buy consensus (90.9%) and institutional interest support upside, but profitability challenges and a class action lawsuit pose risks. Revenue growth and operational improvements are key catalysts, yet high debt-to-asset ratios and negative margins require monitoring for sustained recovery.

XYZ stock trades at $80.10, down 3.21% over 24 hours, with a bearish technical signal and support near $77. Recent earnings show mixed results, beating estimates in Q1 and Q2 2026 but missing in Q4 2025. Revenue growth is modest, with net income margin at 1.43% for 2025. The company is expanding into financial services, applying for a national trust bank charter to offer custody services, as reported by Business Wire on September 8, 2026.

The outlook is cautiously optimistic, with a consensus price target of $100.20 implying 25% upside, supported by 76% buy ratings from analysts. Risks include high P/E ratio of 143.04, regulatory hurdles for new banking initiatives, and volatile cash flows, with net cash flow negative $749 million in 2025. Institutional interest remains strong, with recent buying by Freestone Grove Partners LP noted in a Form 13F filing on August 30, 2026.